estrogens in their naturally occurring water-soluble form, expressed as sodium estrone sulfate.

Misbranding, Section 502 (a), the label statement "Each tablet contains 1.25 mg. of estrogens in their naturally occurring water soluble form, expressed as sodium estrone sulfate" was false and misleading as applied to an article which contained less than the stated amount of estrogens.

DISPOSITION: August 17, 1951. Default decree of forfeiture and destruction.

DRUGS AND DEVICES ACTIONABLE BECAUSE OF FALSE AND MISLEADING CLAIMS*

3574. Misbranding of conjugated estrogens. U. S. v. 1 Bottle * * *. (F. D. C. No. 30960. Sample No. 13099-L.)

LIBEL FILED: June 30, 1951, Northern District of Texas.

ALLEGED SHIPMENT: On or about March 8, 1951, by the Spartan Pharmaceutical Co., from New York, N. Y.

PRODUCT: 1 1000-tablet bottle of conjugated estrogens at Lubbock, Tex.

LABEL, IN PART: "Spartan Conjugated Estrogens."

NATURE OF CHARGE: Misbranding, Section 502 (a), the label statement "Each tablet contains 1.25 Mg. of Estrogens in their naturally occurring water soluble conjugated form expressed as Sodium Estrone Sulfate" was false and misleading as applied to an article which contained 0.78 mg. of total estrogenic steroids calculated as sodium estrone sulfate.

DISPOSITION: October 24, 1951. Default decree of condemnation and destruction.

3575. Misbranding of Dolcin. U. S. v. 164 Cartons * * * *. (F. D. C. No. 27355. Sample No. 13531–K.)

LIBEL FILED: June 23, 1949, District of New Jersey.

ALLEGED SHIPMENT: On or about May 11, 1949, by the Dolcin Corp., from Buffalo, N. Y.

PRODUCT: 164 cartons, each containing 1 bottle, of *Dolcin*, a leaflet entitled "Dolcin," and a business reply card at Trenton, N. J. Analysis indicated that the product consisted essentially of aspirin, 2.6 grains, and calcium succinate, 3.4 grains.

LABEL, IN PART: (Bottle) "Dolcin For Relief of Symptoms Arthritis Rheumatism Dolcin Corporation, New York, N. Y."

NATURE OF CHARGE: Misbranding, Section 502 (a), certain statements on the bottle and carton labels, on the business reply card, and in the leaflet were false and misleading. The statements represented and suggested that the article was adequate and effective for the treatment and cure of rheumatism and arthritis, whereas the article was not effective for such purposes.

Disposition: October 2, 1951. The Dolcin Corp., claimant, having filed an answer denying that the product was misbranded and later having been permitted to withdraw its claim and answer with the understanding that such withdrawal should not be deemed to constitute an admission of the allegations of the libel, judgment of condemnation was entered and the court ordered that the product be destroyed.

^{*}See also Nos. 3550, 3551, 3553, 3565, 3570-3573.